✨ FDA, 성인 주요우울장애 치료제 카플리타 승인
★ 95 전문 정보 ★
THURSDAY, Nov. 13, 2025 — The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults.
This approval marks the fourth indication…
🎯 핵심 특징
✅ 고품질
검증된 정보만 제공
⚡ 빠른 업데이트
실시간 최신 정보
💎 상세 분석
전문가 수준 리뷰
📖 상세 정보
THURSDAY, Nov. 13, 2025 — The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults.
This approval marks the fourth indication…